Equity Overview
Price & Market Data
Price: $0.63
Daily Change: +$0.0481 / 7.63%
Range: $0.57 - $0.67
Market Cap: $18,314,780
Volume: 720,913
Performance Metrics
1 Week: 3.45%
1 Month: -25.00%
3 Months: -23.95%
6 Months: -55.56%
1 Year: -50.00%
YTD: -20.00%
Company Details
Employees: 31
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase 2b clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase 1b clinical trial to treat patients with metabolic dysfunction-associated steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.